0
0

FDA Regulatory Efficiency Act

1/11/2023, 1:29 PM

Congressional Summary of S 2187

FDA Regulatory Efficiency Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a third-party quality system assessment program to accredit persons to assess whether a medical device manufacturer's quality system can ensure the safety and effectiveness or substantial equivalence of an approved medical device after certain changes, including changes in manufacturing or changes to enhance device safety.

Device manufacturers with quality systems that have been certified by an accredited person are allowed to make changes to a device without submitting to the FDA the premarket notification, 30-day notice, or premarket approval supplement that would otherwise be required.

An accredited person who assesses a device manufacturer's quality system must submit a summary of their assessment and, as appropriate, a certification of the quality system to the FDA within 30 days of the assessment. An assessment summary and certification is deemed accepted by the FDA 30 days after submission unless the FDA determines that additional information is needed to support certification, the assessment or certification is unwarranted, or an action other than acceptance of the certification is otherwise justified.

Device manufacturers who make changes to devices without submitting a premarket notification must describe the changes in an annual summary submitted to the FDA. Changes made without submitting a 30-day notice or a premarket approval supplement must be described in a periodic report.

Certifications accepted by the FDA remain in effect for two years.

The FDA must report on this quality system assessment program no later than January 31, 2022. The program is terminated at the end of FY2022.

Current Status of Bill S 2187

Bill S 2187 is currently in the status of Bill Introduced since October 21, 2015. Bill S 2187 was introduced during Congress 114 and was introduced to the Senate on October 21, 2015.  Bill S 2187's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of October 21, 2015

Bipartisan Support of Bill S 2187

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 2187

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Health technology, devices, supplies
- Product safety and quality

Alternate Title(s) of Bill S 2187

FDA Regulatory Efficiency Act
A bill to establish a third-party quality system assessment program.
FDA Regulatory Efficiency Act

Comments

Latest Bills

Healthy Watersheds, Healthy Communities Act of 2026
Bill S 4234April 21, 2026
PPLI Abuse Act
Bill S 4279April 21, 2026
GRATS Act
Bill S 4287April 21, 2026
No Taxes on Utility Bills Act
Bill HR 8350April 21, 2026
Expressing the sense of the House of Representatives that the Department of Justice must comply with the Domestic Emoluments Clause of the Constitution by refusing to administratively settle the billions of dollars in legal claims filed against the United States by President Donald Trump.
Bill HRES 1185April 21, 2026
Rural Utilities Service Modernization Act
Bill HR 8146April 21, 2026
Senior Hunger Prevention Act of 2026
Bill HR 8256April 21, 2026
Consumer Data Privacy and Security Act of 2026
Bill S 4211April 21, 2026
Directing the President, pursuant to the War Powers Resolution, to comply with the 60-day use of force and 30-day phased withdrawal requirements regarding the use of the United States Armed Forces in Operation Epic Fury in Iran.
Bill HJRES 156April 21, 2026
Expressing the sense of the House of Representatives that President Donald Trump, his Special Envoy Steven Witkoff, and all Federal officials must comply with the Foreign Emoluments Clause of the Constitution by immediately turning over to the Department of the Treasury any payments received from the United Arab Emirates or any other foreign state and divest from all business interests linked to foreign governments.
Bill HRES 1186April 21, 2026
21st Century Cures Act
Bill HR 6January 11, 2023
Financial CHOICE Act of 2016
Bill HR 5983January 11, 2023
To amend the Federal Food, Drug, and Cosmetic Act with respect to third-party quality system assessment.
Bill HR 2422January 11, 2023